Isotonic designs for phase I trials

Controlled Clinical Trials

Volumn 22, Issue 2, 2001, Pages 126-138

  Leung, Denis Heng Yan ^a   Wang, You Gan ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Continual reassessment method; Dose escalation; Isotonic regression; Maximum tolerated dose; Phase I trials; Up and down method

Indexed keywords

ARTICLE; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; TOXICITY;

CLINICAL TRIALS, PHASE I; DRUG THERAPY; HUMANS; MAXIMUM TOLERATED DOSE; REGRESSION ANALYSIS; RESEARCH DESIGN;

EID: 0035075179     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(00)00132-X     Document Type: Article

References (15)

1. Stochastic approximation methods and their use in bioassay and phase I clinical trials
2. Design and analysis of phase I clinical trials
3. A comparison of two phase I trial designs
4. Continual reassessment method: A practical design for phase I clinical studies in cancer
5. Methods for dose finding studies in cancer clinical trials: A review and results of a Monte Carlo study
6. Some practical improvements in the continual reassessment method for phase I studies
7. The continual reassessment method in cancer phase I clinical trials: A simulation study
8. A stopping rule for the continual reassessment method
9. Adaptive design improvements in the continual reassessment method for phase I studies
10. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses
11. Continual reassessment method: A likelihood approach
12. Optimal Bayesian-feasible dose escalation for cancer phase I trials
13. Cancer phase I clinical trials: Efficient dose escalation with overdose control
14. An evaluation of phase I cancer clinical trial designs
15. Isotonic inference